Article Details
Retrieved on: 2025-01-24 00:38:59
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Abelacimab, a factor XI inhibitor, demonstrated a 62–69% reduction in major bleeding compared to rivaroxaban in atrial fibrillation patients at ...
Article found on: www.news-medical.net
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here